Stay updated with breaking news from Cell Therapy Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pivotal trials TRANSCEND FL and TRANSCEND NHL 001 continue to underscore the transformative potential of Breyanzi and its clinically meaningful benefit across the broadest array of B-cell... | May 30, 2023
Study shows 18.4% of patients with relapsed or refractory chronic lymphocytic leukemia treated with lisocabtagene maraleucel achieved a complete response (CR), with median duration of CR not reached at median follow-up of 21.1 months.
TRANSCEND CLL 004 is the first pivotal multicenter trial to evaluate a CAR T cell therapy in heavily pre-treated patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic... | May 25, 2023
The therapy had a clinically meaningful response in patients with relapsed or refractory (R/R) follicular lymphoma and R/R mantle cell lymphoma.
CAR T-cell therapy Breyanzi has been approved by the European Commission (EC) based on significant results from a lymphoma Phase III trial.